Literature DB >> 8774418

Intra vitam lumbar cerebrospinal fluid and serum and postmortem ventricular immunoreactive apolipoprotein E in patients with Alzheimer's disease.

N Rösler1, I Wichart, K A Jellinger.   

Abstract

Using a specific enzyme linked immunosorbent assay (ELISA) method, total apolipoprotein E immunoreactivity (tApoE-IR) was measured in premortem lumbar CSF and serum of patients with "probable" Alzheimer's disease and in postmortem ventricular CSF of patients with Alzheimer's disease confirmed by necropsy. Concentrations were compared with those from patients with other neurological diseases and controls. The mean serum:lumbar CSF ratio of ApoE-IR was 15.9 suggesting that the main portion of lumbar ApoE-IR is synthesised intrathecally. No significant differences in ApoE-IR between patients with Alzheimer's disease and the other groups were detected in either CSF compartment. In lumbar CSF, there was no correlation between ApoE-IR of patients with Alzheimer's disease and their mini mental state scores. These results suggest that the diagnostic value of ApoE-IR measurements in CSF of patients with Alzheimer's disease as a single determination is less than that of other markers, in particular tau protein. On the other hand, ApoE determinations could be useful as part of a neurochemical profile of Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8774418      PMCID: PMC1073906          DOI: 10.1136/jnnp.60.4.452

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  15 in total

1.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

2.  Increased levels of tau protein in cerebrospinal fluid of patients with Alzheimer's disease--correlation with degree of cognitive impairment.

Authors:  C Hock; S Golombowski; W Naser; F Müller-Spahn
Journal:  Ann Neurol       Date:  1995-03       Impact factor: 10.422

3.  Total tau protein immunoreactivity in lumbar cerebrospinal fluid of patients with Alzheimer's disease.

Authors:  N Rösler; I Wichart; K A Jellinger
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-02       Impact factor: 10.154

4.  Clinical relevance of the quantification of apolipoprotein E in cerebrospinal fluid.

Authors:  J Carlsson; V W Armstrong; H Reiber; K Felgenhauer; D Seidel
Journal:  Clin Chim Acta       Date:  1991-02-15       Impact factor: 3.786

5.  Apolipoprotein E: binding to soluble Alzheimer's beta-amyloid.

Authors:  T Wisniewski; A Golabek; E Matsubara; J Ghiso; B Frangione
Journal:  Biochem Biophys Res Commun       Date:  1993-04-30       Impact factor: 3.575

6.  Cerebrospinal fluid apolipoprotein E is reduced in Alzheimer's disease.

Authors:  K Blennow; C Hesse; P Fredman
Journal:  Neuroreport       Date:  1994-12-20       Impact factor: 1.837

7.  Clinical-neuropathological correlations in Alzheimer's disease and related dementias.

Authors:  D Galasko; L A Hansen; R Katzman; W Wiederholt; E Masliah; R Terry; L R Hill; P Lessin; L J Thal
Journal:  Arch Neurol       Date:  1994-09

8.  Senile dementia of the Alzheimer type: is there a correlation between entorhinal cortex and dentate gyrus lesions?

Authors:  M C Senut; M Roudier; P Davous; C Fallet-Bianco; Y Lamour
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

9.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.

Authors:  W J Strittmatter; A M Saunders; D Schmechel; M Pericak-Vance; J Enghild; G S Salvesen; A D Roses
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

Review 10.  Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease.

Authors:  J Poirier
Journal:  Trends Neurosci       Date:  1994-12       Impact factor: 13.837

View more
  2 in total

1.  Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of Alzheimer's disease patients.

Authors:  N Rösler; I Wichart; K A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2001       Impact factor: 3.575

2.  Central nervous system lipoproteins in Alzheimer's disease.

Authors:  T J Montine; K S Montine; L L Swift
Journal:  Am J Pathol       Date:  1997-12       Impact factor: 4.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.